1-3 of 3
Supratik Basu, MBBS, MD FRCP, FRCPath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Nizar Bahlis, MD, Thierry Facon, MD, Saad Z. Usmani, MD, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD, PhD, Cyrille Touzeau, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MBBS, FRACP, FRCPA, MD, Hartmut Goldschmidt, Michael E O'Dwyer, MD, Christopher P Venner, MD, Katja C. Weisel, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2019) 134 (Supplement_1): 1875.
https://doi.org/10.1182/blood-2019-123426
Published: 2019
Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Thierry Facon, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD PhD, Philippe Moreau, Nizar Bahlis, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Hartmut Goldschmidt, MD, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, MD FRCPC, Katja Weisel, MD, Joseph R. Mace, Tahamtan Ahmadi, Christopher Chiu, PhD, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, MD, Ming Qi, MD PhD, Saad Z. Usmani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): LBA-2.
https://doi.org/10.1182/blood-2018-120737
Published: 2018
Journal Articles

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Katja Weisel, MD, Meletios A Dimopoulos, MD, Philippe Moreau, Munci Yagci, Alessandra Larocca, MD, Abraham S. Kanate, MD, Filiz Vural, Nicola Cascavilla, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Peter Johnson, Peter D. Byeff, MD, Marek Hus, Paula Rodriguez Otero, MD, Kosei Matsue, MD PhD, Ercan Muelduer, Pekka Anttila, MD, Patrick Hayden, Maria-Theresa Krauth, MD, Dina Ben-Yehuda, MD, Larisa P. Mendeleeva, MD PhD Prof, Shien Guo, Lea Purnomo, Xin Yu, Lara Grote, Tsvetan Biyukov, MD, Mohamed Zaki, MD PhD, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 1960.
https://doi.org/10.1182/blood-2018-99-112155
Published: 2018